NovoCure (NVCR) Return on Sales (2014 - 2026)

NovoCure (NVCR) posted Return on Sales of 0.0% for Q2 2026, up 79.13% sequentially from 0.0% in Q1 2026, and little changed YoY from 0.0% in Q2 2025.

NovoCure (NVCR) Return on Sales (2014 - 2026) Analysis & Trends

NovoCure has reported Return on Sales for 13 years, with the latest figure at 0.0% in Q2 2026.

Quarterly Return on Sales changed 0.0% year-over-year to 0.0% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.0% (changed 0.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
Return on Sales rose to 0.0% in Q2 2026 per NVCR's latest filing, from 0.0% in the prior quarter.
Over five years, Return on Sales peaked at 0.0% in Q1 2022 and troughed at 0.0% in Q2 2023.
A 5-year average of 0.0% and a median of 0.0% in 2025 frame the typical range for Return on Sales.
The widest YoY moves for Return on Sales: up 0 bps in 2022, down 0 bps in 2022.
Over 5 years, Return on Sales stood at 0.0% in 2022, then decreased by 21 bps to 0.0% in 2023, then dropped by 16 bps to 0.0% in 2024, then jumped by 66 bps to 0.0% in 2025, then surged by 39 bps to 0.0% in 2026.
According to Business Quant data, Return on Sales over the past three periods registered 0.0%, 0.0%, and 0.0% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	0.00%
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	0.00%
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	0.00%
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	0.00%
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	0.00%
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	0.00%
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	0.00%
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	0.00%
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	0.00%
10	NovoCure	2.06 Bn	1.62 Bn	142.48 Mn	0.00%

Download Data